Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut check: where you absorb fatty acids matters

NCT ID NCT06082726

Knowledge-focused Sponsor: KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how short-chain fatty acids (SCFAs) enter the bloodstream when delivered to different parts of the gut. Thirteen healthy adults took capsules that released SCFAs in either the small intestine or the colon. Researchers took blood samples over 12 hours to compare absorption. The goal is to better understand how the body processes these important nutrients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
short-chain fatty acids (SCFA)
What this could lead to
If successful, this could improve understanding of how SCFAs are absorbed, potentially guiding future dietary or therapeutic strategies for gut health.
What could go wrong
This is a small, early-stage study in healthy volunteers, not a treatment trial. Results may not apply to people with digestive conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Oct 2023

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * female and male * healthy participants * age within 18 - 50 years * normal BMI (18.5-25 kg/m\^2) Exclusion Criteria: * Chronic gastrointestinal disorders such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, chronic constipation (less than 3 stools a week) and chronic frequent diarrhoea (more than 3 stools a day) * Previous abdominal surgery, except from appendectomy * Being on a weight loss, gluten-free, lactose-free, or vegan diet * The donation of blood during the last 3 months or suffering from low blood haemoglobin levels * The use of antibiotics or other medication that affects the gastrointestinal tract 3 months preceding the study and/or during the study * The use of prebiotics or probiotics 2 weeks preceding the study and/or during the study * Pregnancy, lactation or wish to become pregnant during the study period * Previous or current substance/alcohol dependence or abuse (\> 2 units per day/14 units per week)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intestinal absorption are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intestinal absorption Metabolism Short chain fatty acids Systemic availability

Contacts and locations

Locations

  • KU Leuven

    Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.